Stoneridge Investment Partners’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Stoneridge Investment Partners’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-35	Closed	-$26K	–	249
2017 Q4	$26K	Sell	35 -2	-5%	-$772	﹤0.01%	219
2017 Q3	$11K	Hold	37	–	–	﹤0.01%	238
2017 Q2	$10K	Sell	37 -103	-74%	-$27.7K	﹤0.01%	251
2017 Q1	$46K	Sell	140 -53	-27%	-$24.6K	0.01%	305
2016 Q4	$116K	Hold	193	–	–	0.02%	279
2016 Q3	$219K	Sell	193 -1	-0.5%	-$1.08K	0.03%	242
2016 Q2	$213K	Hold	194	–	–	0.03%	252
2016 Q1	$250K	Sell	194 -82	-30%	-$117K	0.04%	250
2015 Q4	$678K	Sell	276 -43	-13%	-$66K	0.09%	182
2015 Q3	$352K	Sell	319 -5	-2%	-$5.79K	0.05%	232
2015 Q2	$326K	Buy	324 +95	+41%	+$102K	0.04%	240
2015 Q1	$233K	Buy	229 +135	+144%	+$446K	0.03%	242
2014 Q4	$312K	Buy	94 +20	+27%	+$61.3K	0.04%	215
2014 Q3	$216K	Buy	+74	New	+$245K	0.03%	220

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Stoneridge Investment Partners's NBSE Position: Q1 2018 in Review

Stoneridge Investment Partners sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 35 shares — an estimated $26K sold.

Stoneridge Investment Partners first reported a position in NBSE in Q3 2014 and held it in 14 quarters. The position peaked at $678K in Q4 2015. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

Stoneridge Investment Partners reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Stoneridge Investment Partners sold 35 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $26K.
Stoneridge Investment Partners first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2014 and held it in 14 quarters.
Stoneridge Investment Partners's NeuBase Therapeutics, Inc. Common Stock position peaked at $678K in Q4 2015.
35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Stoneridge Investment Partners's 13F filing for Q1 2018, filed 27 Apr 2018.